Sensome have developed a revolutionary sensing technology that combines impedance-based micro-sensors with machine learning algorithms to instantly identify biological tissues upon contact with an unequaled predictive reliability. Its first application is the Clotild® connected guidewire for the treatment of ischemic stroke. Sensome's sensor technology can be deployed in multiple other medical fields, such as interventional cardiology and oncology.
In January of 2020, Sensome raised $9 Million B Round with equity investment from Asahi Intecc, which will go towards testing the clinical performance of their first product, the Clotild® connected guidewire which will be used for the treatment of ischemic stroke. Ischemic stroke can now be treated by removing the clot blocking the brain blood vessel using mechanical thrombectomy devices. At the current moment, the clot is only successfully removed on the first attempt in one of every three cases, however Sensome's new technology will greatly increase their chance, as it will transform these guidewires with it's tissue sensor. Sensome's sensor technology can be deployed in multiple other medical fields, such as interventional cardiology and oncology.
About the founders/CEO:
Franz Bozsak founded Sensome in 2014.
Franz Bozsak obtained a M.S. in Aerospace Engineering from the University of Stuttgart and a Ph.D. from Ecole polytechnique in Biomedical Engineering on the optimization of stents. He is a graduate of the Stanford Ignite/Polytechnique business program. In 2014, he co-founded Sensome and has since brought together a team of renowned scientists, engineers and doctors to realize his vision of connected medical devices. He was named Innovator Under 35 by the MIT Technology Review in 2016.